A cross-sectional study reported that roughly half of patients with binge eating disorder, and about one third of people with atypical anorexia nervosa, have used a prescribed glucagon-like peptide-1 receptor agonist. The finding is described in a Lancet Regional Health article arguing that metabolic prescribing now intersects directly with disordered eating.
GLP-1 receptor agonists are the injectable weight and diabetes drugs built on a gut hormone, semaglutide being the best known of them. The authors note there is no established clinical protocol for screening patients for an eating disorder history before one is prescribed, which is the uncomfortable part of that first number.
Two systems that never talk
The article's central point is structural rather than pharmacological: eating disorder services rarely ask about injecting, and harm reduction services rarely ask about restriction, bingeing or purging. Australia is used as the case study, with the authors framing it as a preview for the broader Western Pacific.
Who the online market reaches
Alongside prescribed use, the authors describe non-prescribed semaglutide and newer peptides such as retatrutide circulating as image and performance enhancing drugs. Adolescents are reported to be acquiring them through online marketplaces with no prescription, age verification or clinical oversight.
That is a demographic shift worth sitting with. Harm reduction literature on performance enhancing drugs was built around young men chasing muscularity, while weight loss and leanness marketing now reaches boys and girls through overlapping channels.
The risks nobody is screening for
Injection site infections, needle reuse and sharing, and blood-borne virus transmission are not routinely assessed at eating disorder intake, according to the authors. Harm reduction models, meanwhile, were never designed around severe restriction or purging, so they do not transfer cleanly either.
The article also reports no validated screening instrument for illicit peptide use in young people with disordered eating, and no evidence base for what to do once use is detected. The recommendation is bidirectional screening in both settings, asked directly and without treating disclosure as treatment failure.
Bottom line
This is a commentary on a gap, not a prevalence survey, and the authors are explicit that population-level data is not yet in. What they argue is that waiting for it leaves clinicians working two separate playbooks for one patient.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.